Walgreen to pay $22.4 million in N.Y. Medicaid improper billing case
Reuters
Published Jul 09, 2015 09:05PM ET
Updated Jul 09, 2015 09:15PM ET
Walgreen to pay $22.4 million in N.Y. Medicaid improper billing case
NEW YORK (Reuters) - Walgreen Co (NYSE:WBA) has reached a $22.4 million settlement with the New York attorney general resolving claims that a unit improperly billed the government for reimbursement for a pediatric drug.
The settlement, disclosed in court papers filed in Manhattan federal court on Thursday, resolves claims first asserted in 2009 by a whistleblower in a lawsuit against Trinity Homecare LLC, a pharmacy primarily owned by Walgreen.
The settlement marked the second in less than two weeks by the New York attorney general and Walgreen over improper conduct and billings by Trinity, after an earlier $2.55 million accord on June 29.
Walgreen agreed to the settlement to avoid delay and expense and did so without any admission of liability, said spokesman James Cohn.
The latest settlement concerned an injectable respiratory drug called Synagis, a brand name drug sold by AstraZeneca Plc that is intended for at-risk premature infants.
According to the whistleblower lawsuit filed by a hospital physician, Susan Vierczhalek, Trinity promoted the off-label use of the drug and caused false claims to be submitted to the government.
In a statement, New York Attorney General Eric Schneiderman said the pharmacy "did not always have a prescription for that drug, but billed Medicaid for it anyway."
"Of greater concern than the improper billing, is the possibility that infants could have received injections which were not properly prescribed to them," he said.
The federal government will receive some of the settlement, while New York will receive $12.23 million, Schneiderman's office said. New York in turn will pay Vierczhalek $4 million as her share of the settlement, according to court papers.
Barbara Hart, Vierczhalek's lawyer, called the settlement "a great fraud recovery for Medicaid and gratifying in all respects."
Representatives for Walgreen did not respond to requests for comment.
Walgreen is part of Walgreens Boots Alliance Inc, and this year sold a majority stake in Trinity's parent Walgreens Infusion Services to private equity firm Madison Dearborn Partners. That business is now known as Option Care.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.